Cargando…
Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events
BACKGROUND: Cardiovascular (CV) disease is a condition with high levels of morbidity and mortality. Canakinumab is a novel monoclonal antibody therapy that has been shown to reduce CV events but is associated with side effects and high cost. The main objective for this analysis is to determine wheth...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123368/ https://www.ncbi.nlm.nih.gov/pubmed/35607490 http://dx.doi.org/10.1016/j.cjco.2022.01.003 |